Immix Biopharma, Inc.
IMMX· Nasdaq
Released Mar 24, 2025, after the close
10-K filed Mar 25, 2025, 84 days after period end · 0001641172-25-000387
derived · Computed from the longer spans the company filed.
No earnings release is on file for this quarter. Its figures came with the 10-K.
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$4.81M | -$5.09M | -$3.80M | -$22.76M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immix Biopharma, Inc. · CIK 1873835 · Engraved from SEC EDGAR
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
ended Dec 31, 2024 · filed Mar 25, 2025 · 84 d after period end
+3.4% from the close of Mar 24, 2025 to the close of Mar 25, 2025, the first after the release.